December 21, 2014     Japanese 
  JCN 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
 
Share:
ShinNippon Agrees Licensing Nasal Drug Delivery Technology to Tokai Pharmaceuticals
 

Tokyo, Aug 4, 2006 (JCN) - ShinNippon Biomedical Laboratories' two subsidiaries, Translational Research Ltd.(TRL) and Bioactis Ltd. have signed general terms of agreement for the licensing and supplying of their patented nasal drug delivery technology in the field of endocrinology to Tokai Pharmaceuticals of Massachusetts, USA.

The nasal drug delivery systems developed by TRL is an injection delivered through the nasal membrane such as insulin for diabetes and morphine for painkiller. Nasal delivery has attracted attention for its high safety feature without causing any irritation in patients.

Bioactis has been developing nasal devices which are user friendly to patients and has highly effective spraying performance. The combination of TRL's nasal technology with quality delivery device is intended to create an effective therapeutic package for improving the patient's quality of life.


By Aki Tsukioka Contributor

Copyright © 2014 JCN. All rights reserved. A division of Japan Corporate News Network KK.


 Company Profile |   Print  |   Alerts
ACN Newswire

 Recent  Shin Nippon Biomedical Laboratories, Ltd. News  
  ShinNippon Agrees Licensing Nasal Drug Delivery Technology to Tokai Pharmaceuticals  (Aug 4, 2006)
  Shin Nippon Biomedical Laboratories, Takeda Pharmaceutical Successfully Complete Joint Research on Cynomolgus Monkey  (June 26, 2006)
  Shin Nippon Biomedical Laboratories Obtains New Knowledge on Drug-metabolizing Enzyme Cytochrome P450  (May 9, 2006)
  Shin Nippon Biomedical Laboratories Subsidiaries, Tokai Pharmaceuticals to Collaborate in Nasal Drug Delivery Technology  (Nov 25, 2005)
  Shin Nippon Biomedical Laboratories Develops Intranasal Morphine Preparation  (Nov 4, 2004)
  SNBL to Convert Resort Facilities in Kagoshima into Industry-academia R&D Laboratory  (July 9, 2004)
  SNBL and Tranzyme Pharma to Co-develop New Animal Model Using Primates  (Apr 19, 2004)
  SNBL and Osaka City University to Conduct Joint Research on Severe Brain Damage  (Mar 30, 2004)


 
CSR Report Download
Annual Reports

  More >>    
Most Popular


About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)